Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SENSEI BIOTHERAPEUTICS, INC.

(SNSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SENSEI BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/08/2021 | 08:04am EST

Item 7.01 Regulation FD Disclosure.

On September 8, 2021, members of management of Sensei Biotherapeutics, Inc. (the "Company") will be discussing an updated company overview presentation during virtual one-on-one investor meetings. A copy of this slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits



Exhibit
Number                                Exhibit Description

99.1           Company Presentation.

104          The cover page from Sensei Biotherapeutics, Inc.'s Form 8-K filed on
             September 8, 2021, formatted in Inline XBRL.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SENSEI BIOTHERAPEUTICS, INC.
11/19Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Confe..
AQ
11/16SENSEI BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
11/12Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA..
GL
11/12Sensei Biotherapeutics Presents Preclinical Data for SNS-101, at the Society for Immuno..
CI
11/10SENSEI BIOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/09Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlight..
PU
11/09Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended Septe..
CI
11/09Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlight..
GL
11/03Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on T..
AQ
10/01SENSEI BIOTHERAPEUTICS : to Present New Preclinical Data for SNS-101, a Proprietary Anti-V..
AQ
More news
Analyst Recommendations on SENSEI BIOTHERAPEUTICS, INC.
More recommendations